TY - JOUR
T1 - Effects of an Intervention to Improve Evidence-Based Care for People with Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups
T2 - Insights from the COORDINATE-Diabetes Trial
AU - Tannu, Manasi
AU - Kaltenbach, Lisa
AU - Pagidipati, Neha J.
AU - McGuire, Darren K.
AU - Aroda, Vanita R.
AU - Pop-Busui, Rodica
AU - Kondamudi, Nitin
AU - Al-Khalidi, Hussein R.
AU - Lopes, Renato D.
AU - Cavender, Matthew A.
AU - Nelson, Adam J.
AU - Kirk, Julienne
AU - Lingvay, Ildiko
AU - Magwire, Melissa
AU - Richardson, Caroline Regina
AU - Webb, Laura
AU - Leyva, Monica
AU - Pandey, Ambarish
AU - Washington, Alana
AU - Pak, Jonathan
AU - Gaynor, Tanya
AU - Khan, Waqar
AU - Weston, Patrick
AU - Granger, Christopher B.
AU - Green, Jennifer
N1 - Publisher Copyright:
© 2024 American Heart Association, Inc.
PY - 2024/7/16
Y1 - 2024/7/16
N2 - BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity. METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location. RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; Pinteraction=0.44), race (Black versus White; Pinteraction=0.59), and ethnicity (Hispanic versus Non-Hispanic; Pinteraction= 0.78). CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03936660.
AB - BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity. METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location. RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; Pinteraction=0.44), race (Black versus White; Pinteraction=0.59), and ethnicity (Hispanic versus Non-Hispanic; Pinteraction= 0.78). CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03936660.
KW - cardiovascular diseases
KW - clinical trial
KW - diabetes mellitus, type 2
KW - evidence-based medicine
KW - health disparate minority and vulnerable populations
UR - http://www.scopus.com/inward/record.url?scp=85198925900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198925900&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.124.068962
DO - 10.1161/CIRCULATIONAHA.124.068962
M3 - Article
C2 - 38934111
AN - SCOPUS:85198925900
SN - 0009-7322
VL - 150
SP - 180
EP - 189
JO - Circulation
JF - Circulation
IS - 3
ER -